EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system

Unerwünschte Ereignisse bei verschiedenen Applikationswegen von Amiodaron: Pharmakovigilanzstudie auf Basis des FDA-Adverse-Event-Reporting-Systems

Jingrong Yang, Mengfan You, Jingxin Wang, Rongfei Sun, Lili Han, Xiaonan Liu, Kaibin Niu, Kaidi Xing, Juanping Sun, Wenge Su, Yifei Wang

Frontiers in Pharmacology · 27.01.2025 · 16

DOI: 10.3389/fphar.2025.1517616 ↗

Auf einen Blick

FAERS-Daten zeigen unterschiedliche unerwünschte Ereignisse bei intravenösem und oralem Amiodaron. Der Beginn der Reaktionen war bei i.v. Gabe früher als bei oraler Gabe.

Fragestellung

Unterscheiden sich Spektrum und Zeitpunkt unerwünschter Ereignisse bei intravenösem versus oralem Amiodaron?

Methode

Auswertung von FAERS-Daten von 2004 bis zum 1. Quartal 2024 mit Disproportionalitätsanalyse, ROR und Weibull-Verteilung.

Ergebnisse

16.749 Berichte zu Amiodaron. 2.412 Ereignisse bei i.v. und 8.220 bei oraler Gabe. Kardiale und hepatische AEs häufiger i.v., pulmonale und schilddrüsenbezogene AEs häufiger oral. Medianer Beginn: 5 vs. 74 Tage.

Schlussfolgerung der Autor:innen

Amiodaron zeigte je nach Applikationsweg unterschiedliche Nebenwirkungen und unterschiedliche Zeit bis zum Auftreten.

Kernaussagen

  • Kardiale und hepatische AEs häufiger bei i.v. Amiodaron
  • Pulmonale und schilddrüsenbezogene AEs häufiger bei oraler Gabe
  • Medianer AE-Beginn: 5 Tage i.v. vs. 74 Tage oral

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 27.01.2025. Verfasst von Jingrong Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shandong University of Traditional Chinese Medicine, Jinan, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Arrhythmias are prevalent cardiac disorders with significant impacts on patient quality of life and mortality. Amiodarone, a class III antiarrhythmic agent, is widely used to manage both atrial and ventricular arrhythmias due to its efficacy in prolonging the cardiac action potential and its multiple antiarrhythmic properties. While clinical trials have highlighted the safety and efficacy of amiodarone, there is limited real-world data on adverse events (AEs) associated with different administration routes. This study aims to address this gap by utilizing the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) to investigate the spectrum and timing of AEs related to amiodarone administration through disproportionality analysis and stratification methods.

Methods

Data from the FAERS database were analyzed using disproportionality analysis and reporting odds ratio (ROR) methods for comparative analysis, and the Weibull distribution for time-to-adverse-event analysis. The study examined data from 2004 through the first quarter of 2024 to analyze adverse event signals and the time of occurrence between intravenous and oral amiodarone administration.

Results

A total of 16,749 records of adverse reactions associated with amiodarone were identified. Among these, 2,412 events were related to intravenous amiodarone, and 8,220 events were related to oral amiodarone. The analysis revealed that cardiac and hepatic AEs were more common with intravenous administration, while pulmonary and thyroid-related AEs were more frequent with oral administration. Furthermore, the onset of adverse reactions varied significantly between the routes. The Weibull distribution analysis showed a median onset time of 5 days for intravenous administration compared to 74 days for oral administration. Both routes exhibited early failure-type signals, indicating a decreasing risk of AEs over time.

Conclusion

Amiodarone exhibits varying adverse drug reactions and onset times across different routes of administration. Clinicians should carefully consider these differences when selecting the administration route to balance the risks of adverse reactions with therapeutic benefits.

Schlagwörter

Stichwörter der Autor:innen

FDAadverse eventsamiodaroneintravenousoral

Autor:innen und Institutionen

  • Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Heart Center, Shandong Public Health Clinical Center, Jinan, China.
  • Department of Cardiology, Zhangdian District Hospital of Traditional Chinese Medicine, Zibo, China.
  • Department of Cardiovascular, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Zitieren

APA

Yang, J., You, M., Wang, J., Sun, R., Han, L., Liu, X., Niu, K., Xing, K., Sun, J., Su, W., & Wang, Y. (2025). Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1517616

Vancouver

Yang J, You M, Wang J, Sun R, Han L, Liu X, et al. Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1517616

BibTeX
@article{Yang2025,
  author = {Yang, Jingrong and You, Mengfan and Wang, Jingxin and Sun, Rongfei and Han, Lili and Liu, Xiaonan and Niu, Kaibin and Xing, Kaidi and Sun, Juanping and Su, Wenge and Wang, Yifei},
  title = {Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1517616}
}
Kostenlos starten →